Search for content, post, videos

Sobi to cease ReFacto manufacturing

Guido Oelkers
Sobi has announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF/Xyntha (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. Manufacturing o
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.